Abstract
Background/Objectives: Essential thrombocythemia (ET) is a JAK-STAT-driven myeloproliferative neoplasm with an incompletely defined metabolic phenotype. This study aimed to characterize the plasma metabolome of ET and to determine whether it differs according to JAK2V617F status, platelet count (≥450 vs. 1.5 or 2Y = 0.96; nested cross-validation Q2 = 0.91; permutation p = 0.001). Nineteen metabolites met the criteria: seven Level 1 identifications (succinate, an aminobutyrate isomer, uridine and N-acetylphenylalanine higher; proline, glucuronolactone and quinaldate lower in ET) and twelve Level 3 candidates dominated by platelet-derived eicosanoids, including 11-dehydro-thromboxane B2 (detected in 26% of controls and 99% of patients) and thromboxane B2 (4% and 84%), prostaglandin D2/E2 and B1/A1 isomers, a hydroxy-docosahexaenoic acid isomer, and corticosteroid intermediates. Reactome over-representation analysis, which rests mainly on Level 3 candidates, ranked synthesis of prostaglandins and thromboxanes and arachidonate metabolism highest (FDR 7 × 10−5), followed by fatty acid metabolism, pyrimidine catabolism and, on the basis of Level 3 candidates only, mineralocorticoid biosynthesis. The signature was similar in direction across cytoreductive-therapy, platelet-count and JAK2V617F strata. Conclusions: These exploratory data describe a plasma metabolite signature of aspirin-treated ET dominated by platelet-derived eicosanoids, together with changes in succinate and pyrimidine-related metabolites and candidate changes in corticosteroid intermediates; because aspirin exposure and disease status were fully confounded, the signature requires confirmation with targeted methods in independent cohorts.

This publication has 64 references indexed in Scilit: